Atherosclerosis is the slow build-up of fatty plaque inside artery walls, and it sits behind most heart attacks and strokes. Fisetin has been tested against it in several mouse studies, and the results are consistently positive: less plaque, less lipid in the artery wall, and in some studies lower blood cholesterol [1][2].
Those results come with a hard limit. Every one of them is from mice bred to develop the disease, or from cells in a dish. A 2025 review of the field ends by calling for large randomised clinical trials to establish whether fisetin is safe and effective in people with, or at high risk of, atherosclerotic disease [3]. None has reported. This page goes through what the animal and cell work shows, how the studies were built, and what they cannot tell you.
Key Takeaways
- In apoE knockout mice on a high-fat diet, 12.5 mg/kg of oral fisetin daily for 12 weeks reduced aortic plaque, as did the statin used for comparison [1].
- In the same mouse model, a 2025 study found lower total and LDL cholesterol and more cholesterol excreted in faeces [2].
- In human-derived macrophages, fisetin up to 10 micromolar prevented the formation of foam cells, the lipid-filled cells that seed plaque [4].
- No human trial has tested fisetin for atherosclerosis, cholesterol or plaque.
Important: This article describes animal and laboratory research and is not medical advice. Do not stop or reduce a statin or any other prescribed heart medicine in favour of a supplement. Fisetin can affect enzymes that clear many drugs, so speak to a doctor or pharmacist before adding it, particularly if you take cholesterol, blood pressure or blood-thinning medication.
How the mouse studies are built
Ordinary mice rarely develop atherosclerosis, so researchers use strains missing a gene that clears cholesterol from the blood. The two common ones lack apolipoprotein E (apoE knockout mice) or the LDL receptor (LDLR knockout mice). Fed a high-fat diet, both build plaque in the aorta within weeks. That makes them useful for testing whether a compound slows plaque formation. It also means their cholesterol is far above that of a typical person, driven by a single missing gene.
Where the abstracts describe timing, fisetin was given alongside the high-fat diet from the start. Those designs test whether fisetin slows plaque from forming, not whether it shrinks plaque that has already built up over decades, which is the situation of most adults with heart disease.
Plaque: the head-to-head with a statin
The most directly useful study gave apoE knockout mice on a high-fat diet either fisetin at 12.5 mg/kg, atorvastatin at 2 mg/kg, or nothing, by oral gavage every day for 12 weeks, with 18 mice per group [1]. Untreated mice developed large lipid-rich plaques in the aortic sinus, with less collagen, and had higher total cholesterol, LDL, VLDL and oxidised LDL than normal mice.
Both treatments significantly reduced the plaque and the lipid accumulation in the aortic sinus [1]. Fisetin also lowered aortic levels of PCSK9, a protein that drives LDL cholesterol up and is the target of a class of injectable cholesterol drugs, and LOX-1, the receptor that lets oxidised LDL into artery wall cells. It also reduced the senescence markers p53, p21 and p16 in the aorta.
Two details matter when reading this. The abstract does not say whether fisetin matched the statin or fell short of it, only that both worked. And the statin dose was chosen as a positive control, not to find the best possible result, so this is not evidence that fisetin can replace one.
Cholesterol: where it goes
A 2025 study in the same apoE knockout model looked at what happens to cholesterol itself [2]. Fisetin reduced lipid deposits in the aortic root and in the liver, and lowered blood total cholesterol, triglycerides and LDL cholesterol. Treated mice excreted more neutral sterols, including cholesterol, in their faeces.
The proposed route runs through FXR, a bile acid sensor in the liver and gut [2]. Fisetin changed the levels of liver proteins that make, convert and export cholesterol, and in the small intestine it raised the transporters ABCG5 and ABCG8 while lowering NPC1L1, the protein that absorbs cholesterol from food and the target of the drug ezetimibe. Together this points to increased transintestinal cholesterol excretion, a pathway that moves cholesterol from the blood straight into the gut. FXR as fisetin’s direct target was suggested by computer docking, which is a prediction, not a measurement.
A 2026 study in a different high-cholesterol mouse model also found lower total cholesterol, triglycerides and LDL cholesterol, and less fat in the liver, and pointed to a liver receptor called ASGR1 [5]. Our page on fisetin and liver health covers the fatty liver side of that work.
Foam cells and oxidative stress
Plaque starts when immune cells called macrophages swallow oxidised LDL in the artery wall and swell into lipid-filled foam cells. In macrophages derived from the human U937 cell line, fisetin at up to 10 micromolar did not harm the cells but reduced their lipid accumulation and prevented foam cell formation after exposure to oxidised LDL [4]. It blocked the oxidised LDL-induced rise in reactive oxygen species and the NLRP3 inflammasome that follows, and lowered SREBP-1 and two cholesterol and fat-making enzymes it controls, HMGCR and FAS.
A 2024 study in apoE knockout mice reported lower serum lipids, less plaque, less reactive oxygen species and malondialdehyde, and higher activity of the antioxidant enzymes superoxide dismutase and glutathione peroxidase [6]. It also found more GPX4, an enzyme that protects against ferroptosis, an iron-dependent form of cell death, and less ferritin in treated aortas. Our page on fisetin as an antioxidant explains why antioxidant effects in a dish do not always carry over to people.
For 10 micromolar to mean anything outside a dish, it has to be compared with what people actually reach. 10 micromolar is about 2,862 ng/mL. The peak plasma level after a single 1,000 mg dose of plain fisetin in healthy volunteers was 9.97 ng/mL, and 238.2 ng/mL from a formulated product [7], so 10 micromolar is roughly 12 times the formulated peak. Tissue levels in the artery wall have not been measured.
Diabetes, kidneys and calcified arteries
Diabetes speeds atherosclerosis up. In LDLR knockout mice made diabetic with streptozotocin and fed a high-fat diet containing fisetin for 12 weeks, fisetin reduced the diabetes-worsened atherosclerosis and protected the kidneys [8]. The kidney effect was traced to blocking CD36, a receptor that takes up oxidised fats. Our pages on fisetin and diabetes and fisetin and kidney health cover those areas in more depth.
Calcification hardens arteries and is common in advanced plaque. In aortic smooth muscle cells pushed to calcify with high phosphate, fisetin at 7.5 and 15 micromolar reduced calcification markers [9]. In rats given vitamin D3 and nicotine to calcify their arteries, 100 mg/kg of fisetin a day reduced calcification on ultrasound and tissue staining. That animal arm had three rats per group, which is too few to estimate the size of an effect.
What this does and does not mean for you
The consistency is real. Several studies, using two mouse models and several cell types, report less plaque, lower cholesterol or less foam cell formation. That is why reviewers describe fisetin as a candidate for clinical testing in atherosclerosis [3].
A candidate is not a treatment. Mouse doses do not translate directly to capsules, plain fisetin is poorly absorbed, and better-absorbed formulations are a separate product question; our page on fisetin bioavailability goes through the numbers. The 2026 ASGR1 study is itself partly about that problem: its fisetin nanoparticles lowered lipids at one-fifth the concentration of free fisetin [5].
If you have high cholesterol or heart disease, the treatments with outcome data in people are statins and the other prescribed drugs your doctor can explain. For fisetin’s wider effects on blood vessels as they age, see our page on fisetin and vascular aging, and before combining it with any medication, read fisetin drug interactions.
Common questions
Does fisetin reduce artery plaque?
In apoE knockout mice on a high-fat diet, 12.5 mg/kg of fisetin a day for 12 weeks significantly reduced aortic plaque [1]. It has not been tested for plaque in humans.
Does fisetin lower cholesterol?
In mouse models it lowered total cholesterol, triglycerides and LDL cholesterol [2][5]. No human trial has measured fisetin’s effect on cholesterol.
Can fisetin replace a statin?
No. In one mouse study both fisetin and atorvastatin reduced plaque [1], but statins have decades of outcome data in people and fisetin has none. Do not stop a prescribed statin.
How might fisetin work against atherosclerosis?
The proposed routes include more cholesterol excretion through the gut [2], lower PCSK9 and LOX-1 in the aorta [1], and preventing macrophages from becoming foam cells [4].
Have there been human trials of fisetin for heart disease?
Not for atherosclerosis. A 2025 review calls for large randomised clinical trials to establish safety and efficacy in people at risk [3].
References
- Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice. Exp Ther Med (2021). PMID 33262811
- Fisetin ameliorates atherosclerosis through activating FXR-mediated hepatic cholesterol metabolism and transintestinal cholesterol excretion. Food Res Int (2025). PMID 40922153
- The natural polyphenol fisetin in atherosclerosis prevention: a mechanistic review. J Pharm Pharmacol (2025). PMID 38733634
- Fisetin Prevents Oxidized Low-density Lipoprotein-Induced Macrophage Foam Cell Formation. J Cardiovasc Pharmacol (2021). PMID 34173812
- Fisetin-loaded nanoparticles as a novel approach for cholesterol regulation in hypercholesterolemia: targeting the ASGR1-mediated mTORC1/AMPK pathway. J Nanobiotechnology (2026). PMID 41761201
- Fisetin Suppresses Atherosclerosis by Inhibiting Ferroptosis-Related Oxidative Stress in Apolipoprotein E Knockout Mice. Pharmacology (2024). PMID 38583431
- Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci (2022). PMID 36304817
- Fisetin treatment alleviates kidney injury in mice with diabetes-exacerbated atherosclerosis through inhibiting CD36/fibrosis pathway. Acta Pharmacol Sin (2023). PMID 37225845
- Fisetin Ameliorates Vascular Calcification by Regulating HNRNPA1-Mediated Ferroptosis. Ann Vasc Surg (2026). PMID 40553844
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.